Skip to main content
Premium Trial:

Request an Annual Quote

Clear Labs, Oxford Nanopore Ink North American Distribution Agreement for Food Safety Testing

NEW YORK (GenomeWeb) – Food testing and analytics startup Clear Labs said today that it has signed a US distribution agreement with Oxford Nanopore Technologies (ONT) for rapid food-based pathogen screening technology.

As part of the agreement, Clear Labs will implement ONT's GridIon NGS platform to run its Clear Safety serotyping and detection assays on food samples. The firm said that its bioinformatics software and laboratory automation, paired with the GridIon, will help customers minimize risk, determine results in food specimens within 24 hours, and react quickly to pathogen outbreaks.

"The technology stack we've built at Clear Labs is designed specifically with our customers' needs in mind, with a focus on speed and accuracy at every step," Clear Labs CEO Sasan Amini said in a statement.

In addition to Clear Safety, Clear Labs also supports testing for authenticity, GMO, and microbiome testing.

"When [Clear Labs] approached us about leveraging GridIon in Clear Safety, we saw a unique opportunity to meet a critical business need in the industry a fast turnaround and the ability to fit into a completely automatic system," ONT CEO Gordon Sanghera said in a statement.

For more on how Clear Labs is using Oxford Nanopore sequencing in its food testing workflow, click here.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more